Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Aclaris Therapeutics宣佈與Sun Pharma就Deuruxolitinib的權利達成獨家專利許可協議；協議包括1500萬美元的預付款，外加里程碑和特許權使用費
Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Aclaris Therapeutics宣佈與Sun Pharma就Deuruxolitinib的權利達成獨家專利許可協議；協議包括1500萬美元的預付款，外加里程碑和特許權使用費
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。